PFIZER

Analysis of Pfizer share price

--- Ad ---
BUY   SELL
76.4% of retail investor accounts lose money when trading CFDs with this provider.
 
Chart provided by Tradingview

Latest news

Pfizer and Moderna: More than 350 million additional vaccine doses ordered by Brussels

18/02/2021 - 11h24

Vaccine orders are accelerating in Europe as evidenced by these two new orders for Moderna and Pfizer vaccine doses by the European Commission. Explanations on this news.

Elements that can influence the price of this asset:

Analysis N°1

Firstly, we would of course recommend you monitor all strategic agreements and partnerships that Pfizer implements with other companies or competitors in the pharmaceutical sector. The agreements relating to research and development of new treatments are often positive for the growth of this group and its share price on the stock markets.

Analysis N°2

We would also monitor the health sector requirements worldwide noting frequent illnesses and diseases or those registering a rise for which Pfizer may provide solutions and treatments.

Analysis N°3

Merger and acquisition operations completed abroad, notably in emerging markets are also good indicators of a rise in this asset price and should therefore be monitored.

Analysis N°4

It is also recommended to follow the launch of new products from the group and their success or failure following their entry onto the market that could generate increased sales or losses in income.

Analysis N°5

The regulations in effect relating to the sale of medicines are increasingly strict around the world and it is therefore important to monitor and take into account any changes in them.

Analysis N°6

Finally, as with numerous other activity sectors, that of the pharmaceutical industry continues to suffer from the effects of the European economic downtrend.

76.4% of retail investor accounts lose money when trading CFDs with this provider. Trade CFDs with Plus500

General presentation of Pfizer

The Pfizer Group is the international leader in pharmaceuticals at the present time. Its activities can be separated into several categories including medicines for the treatment of cardiovascular illnesses, nervous system problems, infectious illnesses, urology, ophthalmology and also vaccines and oncology products.

The majority of its turnover is achieved in the United States and Europe. The Pfizer share price is currently quoted on the NYSE ARCA Europe stock market in the Netherlands and is also integrated in the calculation of the Dow Jones stock market Index.

Analysis of Pfizer share price
76.4% of retail investor accounts lose money when trading CFDs with this provider. Trade CFDs with Plus500

The major competitors of Pfizer

The Pfizer group has recorded slightly smaller sales figures over the last few years but retains the number one position worldwide in pharmaceuticals at present. In terms of turnover it is still the largest company in this sector.

Novartis and Roche

Among the most direct competitors we find the Novartis and Roche groups sharing second position in this global classification.

Gilead

The fifth position is taken by Gilead.


The major partners of Pfizer

Pfizer has also developed favourable alliances with some major companies and formed strategic partnerships.

Zhejiang Hisun

In 2012, Pfizer became notably associated with the Chinese company Zhejiang Hisun in order to obtain high quality generic medicines at low prices for the Chinese market.

Matwin

In 2015, the Pfizer group became one of the partners of the MATWIN Company that specialises in oncology projects and is part of the UNICANCER group, thereby joining the ten other member laboratories that participate in this research project.

IBM

In 2016, Pfizer also became associated with the IT company IBM in the creation of remote monitoring solutions for patients suffering from Parkinson’s disease.

76.4% of retail investor accounts lose money when trading CFDs with this provider. Trade CFDs with Plus500
The factors in favour of a rise in the Pfizer share price:

First of all, it is important to remember that the Pfizer Group is one of the giants of the pharmaceutical industry throughout the world. It has been able to achieve this very advantageous positioning thanks to a very strong international presence, as it operates in more than fifty different countries.

This brings us to another of the company's assets, which this time concerns the good geographical distribution of its sources of revenue. By marketing its products throughout the world, Pfizer ensures good protection against geo-economic risks over the long term.

Of course, another strength of the Pfizer Group is its capacity for innovation, which enables it to stand out effectively from the competition by developing products that are both innovative and respond to new consumer needs.  To achieve this goal, Pfizer naturally invests a great deal of money in research and development and employs highly qualified researchers.

In addition, the economic and financial history of the company shows that the Pfizer Group has often been involved in mergers and acquisitions of major pharmaceutical brands around the world. This strategy has, of course, provided the company with a significant expansion and has contributed to strengthening its brand image.

The Pfizer brand is in itself an undeniable asset of the group since it is known worldwide and is associated with a rather positive image among patients, doctors and other pharmacists.

Finally, the Pfizer Group's large workforce of more than 100,000 employees throughout its organisation is of course also an advantage for the future of the group, which can thus respond effectively to demand and new market needs, both in terms of production and development.

The factors in favour of a drop in the Pfizer share price:

First of all, the level of competition in which the Pfizer Group operates is of course a major handicap for its growth opportunities. Indeed, the major pharmaceutical groups mentioned above, which compete directly with Pfizer, are waging a fierce war to retain and take market share. It is therefore particularly difficult for Pfizer to increase its sales in any significant way outside of the release of innovative products or the filing of patents.

Finally, Pfizer's second and last weak point concerns its brand image, which has recently been altered. Indeed, the image of this group has become increasingly negative in the eyes of consumers since the company was accused of having participated in the largest health fraud. The group illegally marketed one of its medicines, causing both mistrust among its customers and also mistrust in the market and among investors who are now reluctant to buy the stock.

The information supplied here is only for indicative purposes and should not be used without the completion of a comprehensive and complete fundamental analysis of this asset notably taking into account exterior data, future publications and announcements and all fundamental events and news that could influence the strengths and weaknesses or make them more or less significant. This information does not in any way constitute recommendations relating to the completion of transactions.

Frequently Asked Questions

When was the Pfizer Company first created?

The Pfizer Company first came into being in 1849 in New York through the association between a German chemist, Charles Pfizer, and his cousin, a confectioner, Charles Erhart. In fact these two men first collaborated with the objective of creating and the large scale manufacturing of a type of confectionary named Santonine which was a remedy for treating intestinal worms but had a bitter taste. The associates had the idea of covering these pills with a nutty layer.  

How to detect the future trends of the Pfizer share price?

To successfully forecast the future trends in Pfizer shares you should complete two distinct types of analysis, the technical and fundamental analyses. For the first analysis you will use the volatility indicators and the online stock market chart trends. For the second you will need to follow all significant publications and events of this group and its activity sector.

76.4% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. Trade CFDs with Plus500